FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 238 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR EMA Recommends Extension of Indications for Avelumab December 17, 2020 Presence of Tumour and Higher Levels of LAG3-positive T-cells in the... November 11, 2025 Cómo compartir los resultados de las pruebas genéticas con la familia March 22, 2022 Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in... December 10, 2020 Load more HOT NEWS FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS... Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy
